Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report

Multiple clinical trials have demonstrated that renin-angiotensin system (RAS) blockade with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers effectively reduces chronic kidney disease (CKD) progression. However, most clinical trials excluded participants with advance...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 2018-12, Vol.72 (6), p.873-884
Hauptverfasser:	Weir, Matthew R., Lakkis, Jay I., Jaar, Bernard, Rocco, Michael V., Choi, Michael J., Kramer, Holly J., Ku, Elaine
Format:	Artikel
Sprache:	eng
Schlagworte:	advanced CKD angiotensin converting enzyme inhibitors (ACEi) angiotensin II receptor blockers (ARBs) Angiotensin Receptor Antagonists - administration & dosage Angiotensin-Converting Enzyme Inhibitors - administration & dosage blood pressure cardiovascular risk chronic kidney disease (CKD) diabetes Disease Progression drug safety end-stage renal disease (ESRD) estimated glomerular filtration rate (eGFR) Evidence-Based Medicine Female Glomerular Filtration Rate - drug effects Humans hypertension Male mortality Prognosis proteinuria RAAS blockade Randomized Controlled Trials as Topic reduced eGFR renal disease progression Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - pathology Renal Insufficiency, Chronic - physiopathology Renin angiotensin aldosterone system (RAAS) Renin-Angiotensin System - drug effects Risk Assessment Severity of Illness Index Survival Analysis Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Multiple clinical trials have demonstrated that renin-angiotensin system (RAS) blockade with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers effectively reduces chronic kidney disease (CKD) progression. However, most clinical trials excluded participants with advanced CKD (ie, estimated glomerular filtration rate [eGFR]
ISSN:	0272-6386 1523-6838
DOI:	10.1053/j.ajkd.2018.06.010